Scribd Logo
Upload

Welcome to Scribd!

  • 108 views

    Vaksin HPV

    Uploaded by

    sutiani
    The document discusses primary prevention of HPV through vaccination. It describes how the HPV vaccine contains empty shells formed through recombinant biotechnology that mimic the viral shape without containing infectious DNA or mercury. The vaccine works by generating antibodies to prevent new infections and infections in other locations. National vaccination programs in Indonesia aim to administer two doses of the HPV vaccine to girls aged 12 or in 6th grade primary school to help prevent cervical cancer, an important women's health issue that can be prevented through vaccination.

    Copyright:

    © All Rights Reserved
    Download as PPT, PDF, TXT or read online from Scribd

    Vaksin HPV

    Uploaded by

    sutiani
    108 views14 pages
    The document discusses primary prevention of HPV through vaccination. It describes how the HPV vaccine contains empty shells formed through recombinant biotechnology that mimic the viral shape without containing infectious DNA or mercury. The vaccine works by generating antibodies to prevent new infections and infections in other locations. National vaccination programs in Indonesia aim to administer two doses of the HPV vaccine to girls aged 12 or in 6th grade primary school to help prevent cervical cancer, an important women's health issue that can be prevented through vaccination.

    Original Title

    Vaksin HPV.ppt

    Copyright

    © © All Rights Reserved

    Available Formats

    PPT, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    The document discusses primary prevention of HPV through vaccination. It describes how the HPV vaccine contains empty shells formed through recombinant biotechnology that mimic the viral shape without containing infectious DNA or mercury. The vaccine works by generating antibodies to prevent new infections and infections in other locations. National vaccination programs in Indonesia aim to administer two doses of the HPV vaccine to girls aged 12 or in 6th grade primary school to help prevent cervical cancer, an important women's health issue that can be prevented through vaccination.

    Copyright:

    © All Rights Reserved
    Download as PPT, PDF, TXT or read online from Scribd
    Download as ppt, pdf, or txt
    108 views14 pages

    Vaksin HPV

    Uploaded by

    sutiani
    The document discusses primary prevention of HPV through vaccination. It describes how the HPV vaccine contains empty shells formed through recombinant biotechnology that mimic the viral shape without containing infectious DNA or mercury. The vaccine works by generating antibodies to prevent new infections and infections in other locations. National vaccination programs in Indonesia aim to administer two doses of the HPV vaccine to girls aged 12 or in 6th grade primary school to help prevent cervical cancer, an important women's health issue that can be prevented through vaccination.

    Copyright:

    © All Rights Reserved
    Download as PPT, PDF, TXT or read online from Scribd
    Download as ppt, pdf, or txt
    You are on page 1of 14

    PRIMARY PREVENTION

    HPV VACCINE
    Teknologi Vaksin HPV

    Empty Shell formed by


    recombinant biotechnology
    to mimic the viral 3D shape.

    Does not contain


    Real
    infectious DNA Virus
    Vaccine

    Does not contain mercury


    (thimerosal)

    GARDASIL is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA.
    *VLP = Virus-like particle.
    1. Villa LL, Costa RL, Petta CA, et al. Lancet Oncol. 2005;6:271278. 2
    Image courtesy of Dr. Ian Frazer
    ID/CER/0015/13 AD 26/07/13 ED 26/07/2015

    Mekanisme perlindungan vaksin


    HPV
    3. Infeksi baru dicegah
    1. Turunnya virus
    2. Infeksi pada tempat setelah tumpahan
    lain dicegah

    IgG antibodies
    Adapted from Schwarz TF & Leo O. Gynecol Oncol 2008; 110: S
    PROPHYLACTIC VACCINE
    Antigens AS04 adjuvant

    + Aluminium
    salt
    (Al(OH)3)
    + MPL
    Immunostimulant

    HPV 16 VLPs HPV 18 VLPs

    AS04-containing vaccine

    QUADRIVALENT
    Antigens Adjuvant

    +
    Aluminium
    Aluminium salt
    salt
    (amorphous
    (amorphous
    aluminium
    aluminium
    hydroxyphosphate
    hydroxyphosphate
    HPV 16 VLPs HPV 18 VLPs HPV 6 VLPs HPV 11 VLPs sulphate
    sulphate [AAHS])
    [AAHS])

    AAHS-containing vaccine
    PEMBERIAN VAKSIN

    Recommended schedule
    Intramuscular injection (IM)

    BIVALENT
    0 1 2 3 4 5 6
    Dosis Dosis Dosis
    1 2 3
    QUADRIVALENT
    Phase III study vs. HAV (PATRICIA): 3 years

    BIVALENT efficacy against CIN regardless of


    HPV type in lesion
    Young women
    (TVC-nave) before sexual
    debut, 1 dose
    Vaccine Placebo
    Estimated Vaccine efficacy1
    prevalence Endpoint N = 5,449 N = 5,436 P-value
    HPV 16/18
    n n % 95 % CI

    2530 %2 CIN1+ 106 211 50.1 35.961.4 <0.0001

    52%3 CIN2+ 33 110 70.2 54.780.9 <0.0001

    up to 70%4 CIN3+ 3 23 87.0 54.997.7 <0.0001

    End of study of PATRICIA5 CIN 3+ 93.2 78.998.7

    1.Paavonen J, et al. Lancet 2009; 374:301314; 2. Clifford GM, et al. Cancer Epi Biom. Prev 2005; 14:11571164; 3. Smith JS, et
    al. Int J Cancer 2007; 121:621632; 4. Cervical cancer data. Available at: www.who.int/hpvcentre/statistics (Accessed 1 May
    2009); 5. Paavonen J, et al. 26th IPvC, Montreal, 3-8 July 2010, abstract 689.
    Vaccine Efficacy
    Per-Protocol Efficacy Population - Protocols 007, 013, 015
    (n=18780)
    HPV Quadrivalen
    t %
    6/11/16/18- Placebo 95% CI
    Related Efficacy
    Vaccine
    CIN 2/3 or
    AIS 1 73 99 92, 100
    Vulval and
    Vaginal
    Lesions (incl. 2 189 99 96, 100
    Genital
    Warts)
    VIN 2/3 or
    VaIN 2/3 0 15 100 72, 100
    PP = received 3 vaccinations within 1 year; no major protocol violations; HPV 16/18 sero(-) at day 1 and HPV
    16/18 DNA(-) day 1 to month 7; cases counted starting after month 7. CIN = cervical intraepithelial neoplasia;
    AIS = adenocarcinoma in situ.
    Average follow up for 3 years
    Guidelines for HPV Vaccination

    Its our responsibility to


    protect our patients

    9
    INDONESIAN HPV VACCINE GUIDELINE

    PROPHYLACTIC VACCINE

    IM DELTOID MUSCLE 10-55 YEARS OLD


    0,1-2,6
    0-6
    SEXUAL (-)
    LACTATION
    HPV VACCINE
    SEXUAL (+)
    NO PREGNANCY PAP SMEAR (-)

    PRECANCER LESION HPV INFECTION


    IN THE PAST IN THE PAST

    NO HPV INFECTION NO PRECANCER LESION


    VACCINATION + PAP SMEAR
    POGI (HOGI)-IDAI
    SPECIFIC DOSE
    MALE HPV VACCINE
    Program Vaksinasi Nasional
    HOGI mengakselerasi program
    nasional vaksinasi
    Program vaksinasi nasional ditujukan
    pada anak perempuan usia 12 tahun
    ATAU kelas 6 Sekolah Dasar dengan
    pemberian 2 dosis
    RINGKASAN

    KANKER SERVIKS
    MERUPAKAN SALAH
    SATU MASALAH DALAM
    KESEHATAN
    KANKER SERVIKS
    DAPAT DICEGAH
    VAKSIN HPV
    MERUPAKAN
    PENCEGAHAN PRIMER

    You might also like